• 1
    Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972; 4: 482-510.
  • 2
    Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma Study Group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998; 9: 893-899.
  • 3
    Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987; 5: 21-26.
  • 4
    Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: 8-year experience with adjuvant chemotherapy. J Cancer Res. Clin Oncol. 1983; 106( suppl): 55-67.
  • 5
    Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998; 80: 1020-1033.
  • 6
    Huvos AG. Bone Tumors: Diagnosis, Treatment, and Prognosis. 2nd ed. Philadelphia, PA: WB Saunders Company; 1991.
  • 7
    Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314: 1600-1606.
  • 8
    Berend KR, Pietrobon R, Moore JO, Dibernardo L, Harrelson JM, Scully SP. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. J Surg Oncol. 2001; 78: 162-170.
  • 9
    Welck MJ, Gikas PD, Pearce P, Bhumbra R, Briggs TW, Cannon S. Local recurrence of osteosarcoma after 17 years. Ann R Coll Surg Engl. 2009; 91: W17-W19.
  • 10
    Nagarajan R, Kamruzzaman A, Ness KK, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer. 2011; 117: 625-634.
  • 11
    Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010; 11: 670-678.
  • 12
    Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003; 21: 1574-1580.
  • 13
    Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009; 21: 345-351.
  • 14
    Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of 2 regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997; 350: 911-917.
  • 15
    Link MP. The multi-institutional osteosarcoma study: an update. Cancer Treat Res. 1993; 62: 261-267.
  • 16
    Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001; 19: 3203-3209.